CHEK2 and non-small cell lung carcinoma: The prevalence in our cohort also exceeds that of Finnish patients in the early‐stage lung adenocarcinoma cohort, where all CHEK2 alterations had a prevalence of 3.7% [9], and that of the MSKCC cohort of advanced NSCLC (< 1%) [16].